Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric I Zimmerman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Acta Neuropathologica|October 5, 2011
Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal regionAlice Y Wang, Kathryn M Lohmann, C Kevin Yang, et al.
Molecular Pharmacology|August 10, 2010
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemiaEric I Zimmerman, Claudia M Dollins, Melissa Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2012
Ontogeny and sorafenib metabolismEric I Zimmerman, Justin L Roberts, Lie Li, et al.
Blood|September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaEric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
Cancer Research|December 19, 2015
Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell DeathEric I Zimmerman, Alice A Gibson, Shuiying Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2013
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemiaSharyn D Baker, Eric I Zimmerman, Yong-Dong Wang, et al.
Clinical Pharmacology and Therapeutics|September 2, 2025
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and PatientsEleanor A Lisbon, R Clark Brown, Andrew Redfern, et al.
Plos One|July 5, 2013
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaMatthew J Cooper, Nathan J Cox, Eric I Zimmerman, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Acta Neuropathologica|October 5, 2011
Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal regionAlice Y Wang, Kathryn M Lohmann, C Kevin Yang, et al.
Molecular Pharmacology|August 10, 2010
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemiaEric I Zimmerman, Claudia M Dollins, Melissa Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2012
Ontogeny and sorafenib metabolismEric I Zimmerman, Justin L Roberts, Lie Li, et al.
Blood|September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaEric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
Cancer Research|December 19, 2015
Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell DeathEric I Zimmerman, Alice A Gibson, Shuiying Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2013
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemiaSharyn D Baker, Eric I Zimmerman, Yong-Dong Wang, et al.
Clinical Pharmacology and Therapeutics|September 2, 2025
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and PatientsEleanor A Lisbon, R Clark Brown, Andrew Redfern, et al.
Plos One|July 5, 2013
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaMatthew J Cooper, Nathan J Cox, Eric I Zimmerman, et al.
Pageof 2